43 related articles for article (PubMed ID: 27158141)
1. Discovery of potent and novel dual NAMPT/BRD4 inhibitors for efficient treatment of hepatocellular carcinoma.
Yin C; Jia S; Yang X; Wu L
Eur J Med Chem; 2024 May; 271():116444. PubMed ID: 38691889
[TBL] [Abstract][Full Text] [Related]
2. Channeling Nicotinamide Phosphoribosyltransferase (NAMPT) to Address Life and Death.
Velma GR; Krider IS; Alves ETM; Courey JM; Laham MS; Thatcher GRJ
J Med Chem; 2024 Apr; 67(8):5999-6026. PubMed ID: 38580317
[TBL] [Abstract][Full Text] [Related]
3. NAMPT knockdown attenuates atherosclerosis and promotes reverse cholesterol transport in ApoE KO mice with high-fat-induced insulin resistance.
Li S; Wang C; Li K; Li L; Tian M; Xie J; Yang M; Jia Y; He J; Gao L; Boden G; Liu H; Yang G
Sci Rep; 2016 May; 6():26746. PubMed ID: 27229177
[TBL] [Abstract][Full Text] [Related]
4. Structure-Based Design of Potent Nicotinamide Phosphoribosyltransferase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
Bai J; Liao C; Liu Y; Qin X; Chen J; Qiu Y; Qin D; Li Z; Tu ZC; Jiang S
J Med Chem; 2016 Jun; 59(12):5766-79. PubMed ID: 27224875
[TBL] [Abstract][Full Text] [Related]
5. Nicotinamide Phosphoribosyltransferase Attenuates Methotrexate Response in Juvenile Idiopathic Arthritis and In Vitro.
Funk RS; Singh R; Pramann L; Gigliotti N; Islam S; Heruth DP; Ye SQ; Chan MA; Leeder JS; Becker ML
Clin Transl Sci; 2016 Jun; 9(3):149-57. PubMed ID: 27166432
[TBL] [Abstract][Full Text] [Related]
6. Gene-gene interactions in the NAMPT pathway, plasma visfatin/NAMPT levels, and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy.
Luizon MR; Palei ACT; Belo VA; Amaral LM; Lacchini R; Duarte G; Cavalli RC; Sandrim VC; Tanus-Santos JE
Pharmacogenomics J; 2017 Oct; 17(5):427-434. PubMed ID: 27168100
[TBL] [Abstract][Full Text] [Related]
7. Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer.
Ju HQ; Zhuang ZN; Li H; Tian T; Lu YX; Fan XQ; Zhou HJ; Mo HY; Sheng H; Chiao PJ; Xu RH
Cancer Lett; 2016 Aug; 379(1):1-11. PubMed ID: 27233476
[TBL] [Abstract][Full Text] [Related]
8. Axon degeneration: context defines distinct pathways.
Geden MJ; Deshmukh M
Curr Opin Neurobiol; 2016 Aug; 39():108-15. PubMed ID: 27197022
[TBL] [Abstract][Full Text] [Related]
9. Sarm1 Deletion, but Not Wld
Gilley J; Ribchester RR; Coleman MP
Cell Rep; 2017 Oct; 21(1):10-16. PubMed ID: 28978465
[TBL] [Abstract][Full Text] [Related]
10. Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities.
Chen H; Wang S; Zhang H; Nice EC; Huang C
Expert Rev Anticancer Ther; 2016 Aug; 16(8):827-38. PubMed ID: 27186719
[TBL] [Abstract][Full Text] [Related]
11. Depletion of NAD pool contributes to impairment of endothelial progenitor cell mobilization in diabetes.
Wang P; Yang X; Zhang Z; Song J; Guan YF; Zou DJ; Miao CY
Metabolism; 2016 Jun; 65(6):852-62. PubMed ID: 27173464
[TBL] [Abstract][Full Text] [Related]
12. The SARM1 TIR domain produces glycocyclic ADPR molecules as minor products.
Garb J; Amitai G; Lu A; Ofir G; Brandis A; Mehlman T; Kranzusch PJ; Sorek R
PLoS One; 2024; 19(4):e0302251. PubMed ID: 38635746
[TBL] [Abstract][Full Text] [Related]
13. A Comprehensive Survey of Prospective Structure-Based Virtual Screening for Early Drug Discovery in the Past Fifteen Years.
Zhu H; Zhang Y; Li W; Huang N
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555602
[TBL] [Abstract][Full Text] [Related]
14. From Rate-Limiting Enzyme to Therapeutic Target: The Promise of NAMPT in Neurodegenerative Diseases.
Zhu Y; Xu P; Huang X; Shuai W; Liu L; Zhang S; Zhao R; Hu X; Wang G
Front Pharmacol; 2022; 13():920113. PubMed ID: 35903330
[TBL] [Abstract][Full Text] [Related]
15. Glioma-Targeted Therapeutics: Computer-Aided Drug Design Prospective.
Poonan P; Agoni C; Ibrahim MAA; Soliman MES
Protein J; 2021 Oct; 40(5):601-655. PubMed ID: 34590194
[TBL] [Abstract][Full Text] [Related]
16. Programmed axon degeneration: from mouse to mechanism to medicine.
Coleman MP; Höke A
Nat Rev Neurosci; 2020 Apr; 21(4):183-196. PubMed ID: 32152523
[TBL] [Abstract][Full Text] [Related]
17. Inhibitor of Nicotinamide Phosphoribosyltransferase Sensitizes Glioblastoma Cells to Temozolomide via Activating ROS/JNK Signaling Pathway.
Feng J; Yan PF; Zhao HY; Zhang FC; Zhao WH; Feng M
Biomed Res Int; 2016; 2016():1450843. PubMed ID: 28097126
[TBL] [Abstract][Full Text] [Related]
18. Application of virtual screening to the discovery of novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with potential for the treatment of cancer and axonopathies.
Clark DE; Waszkowycz B; Wong M; Lockey PM; Adalbert R; Gilley J; Clark J; Coleman MP
Bioorg Med Chem Lett; 2016 Jun; 26(12):2920-2926. PubMed ID: 27158141
[TBL] [Abstract][Full Text] [Related]
19. SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT).
Curtin ML; Heyman HR; Clark RF; Sorensen BK; Doherty GA; Hansen TM; Frey RR; Sarris KA; Aguirre AL; Shrestha A; Tu N; Woller K; Pliushchev MA; Sweis RF; Cheng M; Wilsbacher JL; Kovar PJ; Guo J; Cheng D; Longenecker KL; Raich D; Korepanova AV; Soni NB; Algire MA; Richardson PL; Marin VL; Badagnani I; Vasudevan A; Buchanan FG; Maag D; Chiang GG; Tse C; Michaelides MR
Bioorg Med Chem Lett; 2017 Aug; 27(15):3317-3325. PubMed ID: 28610984
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]